Combined immunosuppressive pathway

The combined immunosuppressive pathway refers to the integrated network of inhibitory signals and metabolic processes that tumors exploit to evade the host immune system (Pardoll, 2012, Nature Reviews Cancer). This concept encompasses multiple distinct molecular targets, including immune checkpoints like Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), and Lymphocyte Activation Gene 3 (LAG-3), as well as metabolic enzymes such as Indoleamine 2,3-dioxygenase (IDO1) (Sharma & Allison, 2015, Science). Tumors often utilize these pathways redundantly to create a suppressive microenvironment that induces T-cell exhaustion and limits the efficacy of monotherapies. Therapeutic intervention typically involves combination strategies, such as the dual blockade of PD-1 and CTLA-4, to overcome resistance and enhance anti-tumor immunity (Wolchok et al., 2017, NEJM). While these combinations can significantly improve patient outcomes, they are also associated with a higher incidence of immune-related adverse events (irAEs) due to the broad activation of the immune system (Postow et al., 2018, NEJM). This entry is classified as incorrect as a single target because it represents a biological concept or therapeutic strategy involving multiple distinct molecular entities rather than a single canonical protein or receptor.

Other names

Immune checkpoint pathwaysImmunosuppressive networkTumor microenvironment immunosuppressionCo-inhibitory signalingCombined immune checkpoint blockade

The mechanism involves the simultaneous or sequential inhibition of multiple non-redundant inhibitory signals (e.g., PD-1, CTLA-4, LAG-3) to restore the activity of effector T-cells and other immune cells within the tumor microenvironment (Pardoll, 2012, Nature Reviews Cancer).